Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Sacituzumab govitecan by Gilead Sciences for Malignant Pleural Mesothelioma: Likelihood of Approval
Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Malignant Pleural Mesothelioma. According to...
Seladelpar lysine by Gilead Sciences for Primary Biliary Cholangitis (Primary Biliary Cirrhosis): Likelihood of Approval
Seladelpar lysine is under clinical development by Gilead Sciences and currently in Pre-Registration for Primary Biliary Cholangitis (Primary Biliary Cirrhosis)....
Brexucabtagene autoleucel by Gilead Sciences for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Brexucabtagene autoleucel is under clinical development by Gilead Sciences and currently in Phase II for Refractory Acute Myeloid Leukemia. According...
Brexucabtagene autoleucel by Gilead Sciences for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Brexucabtagene autoleucel is under clinical development by Gilead Sciences and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According...
Brexucabtagene autoleucel by Gilead Sciences for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Brexucabtagene autoleucel is under clinical development by Gilead Sciences and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute...
Brexucabtagene autoleucel by Gilead Sciences for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Brexucabtagene autoleucel is under clinical development by Gilead Sciences and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute...
Risk adjusted net present value: What is the current valuation of Gilead Sciences's Seladelpar lysine?
Seladelpar lysine is a small molecule commercialized by Gilead Sciences, with a leading Pre-Registration program in Primary Biliary Cholangitis (Primary...
KITE-222 by Gilead Sciences for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According to...
KITE-222 by Gilead Sciences for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...
KITE-222 by Gilead Sciences for Mantle Cell Lymphoma: Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...
KITE-222 by Gilead Sciences for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...
KITE-222 by Gilead Sciences for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to...
KITE-222 by Gilead Sciences for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According...
KITE-222 by Gilead Sciences for Burkitt Lymphoma: Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Burkitt Lymphoma. According to GlobalData, Phase...
KITE-363 by Gilead Sciences for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
KITE-363 is under clinical development by Gilead Sciences and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...
KITE-363 by Gilead Sciences for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
KITE-363 is under clinical development by Gilead Sciences and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
KITE-363 by Gilead Sciences for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
KITE-363 is under clinical development by Gilead Sciences and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According to...
KITE-363 by Gilead Sciences for Mantle Cell Lymphoma: Likelihood of Approval
KITE-363 is under clinical development by Gilead Sciences and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...
KITE-363 by Gilead Sciences for Burkitt Lymphoma: Likelihood of Approval
KITE-363 is under clinical development by Gilead Sciences and currently in Phase II for Burkitt Lymphoma. According to GlobalData, Phase...
KITE-363 by Gilead Sciences for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
KITE-363 is under clinical development by Gilead Sciences and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According...